{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T03:11:00Z","timestamp":1708139460080},"reference-count":3,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,14]]},"abstract":"<jats:p>This retrospective real-world evidence study investigates the efficacy of as-needed dosing of tildrakizumab in patients with mild-to-moderate psoriasis. Patients received the first three standard doses of tildrakizumab, and thereafter used as-needed dosing over the course of 2.5\u2005years, rather than the approved interval of every 12 weeks. Adequate disease control was achieved, reaching a mean Psoriasis Area and Severity Index at the end of follow-up of &amp;lt; 1.<\/jats:p>","DOI":"10.1093\/ced\/llad361","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T17:26:12Z","timestamp":1698254772000},"page":"272-273","source":"Crossref","is-referenced-by-count":0,"title":["Tildrakizumab-induction therapy followed by\u00a0as-needed dosing in patients with mild-to-moderate psoriasis"],"prefix":"10.1093","volume":"49","author":[{"given":"Carlota","family":"Abbad-Jaime de Arag\u00f3n*","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS . Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Berna-Rico*","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS . Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Goas","sequence":"additional","affiliation":[{"name":"Facultad de Medicina, Universidad Francisco de Vitoria , Pozuelo de Alarc\u00f3n , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"P\u00e9rez-Bootello","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS . Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Asunci\u00f3n","family":"Ballester-Martinez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS . Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Ja\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS . Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Oregon Medical Research Center , Portland, OR , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Gonz\u00e1lez-Cantero","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS . Madrid , Spain"},{"name":"Facultad de Medicina, Universidad Francisco de Vitoria , Pozuelo de Alarc\u00f3n , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"2024021702390082900_llad361-B1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1080\/09546634.2018.1443200","article-title":"Defining and treating moderate plaque psoriasis: a dermatologist survey","volume":"29","author":"Knuckles","year":"2018","journal-title":"J Dermatol Treat"},{"key":"2024021702390082900_llad361-B2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024021702390082900_llad361-B3","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1111\/bjd.15722","article-title":"Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)","volume":"177","author":"Blauvelt","year":"2017","journal-title":"Br J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad361\/54705717\/llad361.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/3\/272\/56679048\/llad361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/3\/272\/56679048\/llad361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T02:39:11Z","timestamp":1708137551000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/3\/272\/7329520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":3,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,10,25]]},"published-print":{"date-parts":[[2024,2,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad361","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2023,10,25]]}}}